%D8%A5%D9%8A%D8%AF%D8%A7%D8%B1%D9%88%D8%A8%D9%8A%D8%B3%D9%8A%D9%86%D8%A2%DB%8C%D8%AF%D8%A7%D8%B1%D9%88%D8%A8%DB%8C%D8%B3%DB%8C%D9%86Category:IdarubicinIdarwbicinIdarubicinIdarubicinIdarrubicina%D8%A2%DB%8C%D8%AF%D8%A7%D8%B1%D9%88%D8%A8%DB%8C%D8%B3%DB%8C%D9%86IdarubisiiniIdarubicine%EC%9D%B4%EB%8B%A4%EB%A3%A8%EB%B9%84%EC%8B%A0IdarubicynaIdarubicin%C4%83%D0%98%D0%B4%D0%B0%D1%80%D1%83%D0%B1%D0%B8%D1%86%D0%B8%D0%BDIdarubicinIdarubicinIdarubicin%D0%86%D0%B4%D0%B0%D1%80%D1%83%D0%B1%D1%96%D1%86%D0%B8%D0%BDIdarubicinQ1063862
about
P3354
P3781
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationCombination Chemotherapy in Patients With Newly Diagnosed BPDCNA Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaStandard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic LeukemiaVELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous LeukemiaCombination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic LeukemiaSelinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLTherapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and AdolescentsPravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaMonoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in RemissionPeripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous LeukemiaCombination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous LeukemiaCombination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's LymphomaCombination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's LymphomaStudy Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid LeukemiaCombination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic LeukemiaCombination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous LeukemiaCombination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous LeukemiaCytarabine, Idarubicin, Liposome-encapsulated Daunorubicin-Cytarabine or Decitabine in Treating Older Patients With Acute Myeloid LeukemiaTreatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTSIdarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic SyndromesSafety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALLEpacadostat, Idarubicin and Cytarabine (EIC) in AMLChildhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd SalvagePevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaStudy of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaSafety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 MutationSirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaHDM201 Added to CT in R/R or Newly Diagnosed AMLHepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol EmulsionA Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLDexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
P4844
Differences in Chemosensitivity to Anthracyclines in First Line Acute Myeloid LeukemiaL-Cysteine capped Mn-doped ZnS quantum dots as a room temperature phosphorescence sensor for in-vitro binding assay of idarubicin and DNARedox mechanism of anticancer drug idarubicin and in-situ evaluation of interaction with DNA using an electrochemical biosensor
P921
Q61862273-F04E5029-A7DC-4168-8EBC-E6C4D4AEC228Q61907739-16DA0C4E-CCCA-4B03-AEF6-3CF19B58605AQ61917580-EB332440-019C-4143-B76D-7D80CAF21E30Q61918327-759CB6D4-03A5-4F87-A5F4-8BE4411A1E22Q61921767-287E5A51-7FB0-44F9-8EB6-6D90B1211CF5Q61934748-82E4B38D-7E36-430E-A180-08E38D396592Q61939162-4BE4ED98-9E31-47FB-B6B7-2DC2BAE39564Q61970069-B37AD7E2-EAB4-4C28-A481-0A838D9DC3C1Q61979967-5FB3291B-E177-4F01-B7F2-D042725D852AQ61980943-DD09938F-3102-4B2B-AFDE-3E49ABB25C3EQ62062297-14DD925D-02F0-41CA-B34E-7ED4BABF9518Q62105164-1743F561-D704-4A77-B5D4-AB0BCDD10CFBQ62105613-9ED1EC75-0DFC-45B6-8523-231885C6D843Q62110032-EB9A31B1-4DEE-41EF-AE0C-32401A52B029Q62110196-96172406-0E8B-4AC1-9341-7AEC5FA1D108Q62110351-03E3A2EC-CDB4-4542-B30F-0B3734EE30F3Q62110378-BDB1F540-33C3-4EC7-A554-FFDB873CBEDBQ62110545-ECCA0026-614E-4190-A2A8-8C0114907599Q62110562-B2759392-DC4A-43BB-924C-3F0FA3DAE541Q62110587-E43DF47D-F17B-4BA1-957B-366CE8A3F1B4Q62110880-5AE51E64-6B90-4751-9ADB-E13A688032A2Q62110987-87E9E671-DF21-439B-B57A-F29A47EF03ADQ63013620-B7E20AC3-FD39-4BD0-A7E7-4BD34600A257Q63319090-E5BE8CC7-EB3D-4E85-ACE7-642A8F7A119FQ63336489-BADBD3AC-425E-4761-AED0-13866E6EA6C9Q63340104-73029FD3-9B61-4BB9-B7AB-B2A96141B3C2Q63398830-C902534E-4422-4708-A1A2-11FC95CEDBD9Q63402466-997F234B-B0FC-4B8E-8EB5-E9538D49152FQ63405255-31B7DC5F-F3AE-4F18-95DF-A44499D610B4Q63571887-A05047C6-D3EE-4EEC-803F-6B938A340008Q63572645-60FD8EC1-65FE-4DEE-9E1D-D8C9C86BE22DQ63575178-DFD4E425-6650-46D6-9FD1-E58144DF352FQ63575894-31D27A43-2120-4F6B-88CE-9520156B908CQ63578207-120C90E8-9B31-4ADB-90F8-FAFF78BB0997Q63578421-7301F9C2-CEA7-4D8C-8070-6432A7929DD4Q63590931-B1F147EB-713C-4913-A9DD-EB7A66C9462CQ63592217-96809CBA-7661-49D0-9F38-833A814ECA18Q63596878-F7B92762-2F99-4114-889C-71168C64E461Q63599325-23D1150B-C1DE-457D-8186-107EA12AE53DQ63599929-93D529F3-44F2-4B2F-9F61-A6423EAFAA8E
P4844
description
Zytostatikum
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Idarrubicina
@es
Idarubicin
@de
Idarubicin
@de-ch
Idarubicin
@en-ca
Idarubicin
@en-gb
Idarubicin
@nl
Idarubicin
@sh
Idarubicin
@sr
Idarubicin
@sv
Idarubicin
@vi
type
label
Idarrubicina
@es
Idarubicin
@de
Idarubicin
@de-ch
Idarubicin
@en-ca
Idarubicin
@en-gb
Idarubicin
@nl
Idarubicin
@sh
Idarubicin
@sr
Idarubicin
@sv
Idarubicin
@vi
altLabel
(1S,3S)-3-Acetyl-3,5,12-trihyd ...... xy-alpha-L-lyxo-hexopyranoside
@en
4-Demethoxydaunomycin
@en
4-Demethoxydaunorubicin
@en
5,12-Naphthacenedione, 9-acety ...... -6,9,11-trihydroxy-, (7S-cis)-
@en
58957-92-9
@fr
C28H31NO7
@fr
IMI-30
@cy
IMI-30
@en
Idamycin®
@cy
Idamycin®
@en
prefLabel
Idarrubicina
@es
Idarubicin
@de
Idarubicin
@de-ch
Idarubicin
@en-ca
Idarubicin
@en-gb
Idarubicin
@nl
Idarubicin
@sh
Idarubicin
@sr
Idarubicin
@sv
Idarubicin
@vi